BiondVax Pharmaceuticals Ltd. is developing an innovative universal flu (influenza) vaccine, providing a multi-season/multi-strain and long-term protection against a variety of flu viruses. The universal flu vaccine is currently in phase 1 clinical trials in humans.
The company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing this innovative flu vaccine.
BiondVax’s offices and laboratories are located at Kiryat Weizmann Science Park, Ness-Ziona, Israel.
